CD46 and Miyoshi myopathy: CD46 is an intriguing candidate with which to target MM-ICs, because (1) it is a complement inhibitor that may help MM-ICs survive and (2) a subset of high-risk MM patients have a genomic gain of CD46 on chromosome 1q (1q+).